e-learning
resources
Madrid 2019
Monday, 30.09.2019
Extra-pulmonary tuberculosis and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antituberculosis drug- induced hepatitis, an unpredictable phenotype
M. da Silva Alcobia (Coimbra, Portugal), L. M Nogueira (Coimbra, Portugal), B. Oliveiros (Coimbra, Portugal), C. Robalo Cordeiro (Coimbra, Portugal), H. C Silva (Coimbra, Portugal)
Source:
International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Session:
Extra-pulmonary tuberculosis and comorbidities
Session type:
Thematic Poster
Number:
2986
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. da Silva Alcobia (Coimbra, Portugal), L. M Nogueira (Coimbra, Portugal), B. Oliveiros (Coimbra, Portugal), C. Robalo Cordeiro (Coimbra, Portugal), H. C Silva (Coimbra, Portugal). Antituberculosis drug- induced hepatitis, an unpredictable phenotype. 2986
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Identifying genetic susceptibility to isoniazid- induced hepatitis
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy
Source: Eur Respir J 2009; 33: 1518-1519
Year: 2009
The risk of hepatotoxicity of anti-tuberculosis drugs in patients from regions with high prevalence of hepatitis B
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis
Source: ISSN=ISSN 1810-6838, ISBN=, page=69
Year: 2007
The influence phenotype of hydroxylation on anti-tuberculosis drug-induced hepatotoxicity
Source: Eur Respir J 2006; 28: Suppl. 50, 505s
Year: 2006
Fulminant hepatitis during antituberculosis chemotherapy: five case reports
Source: Eur Respir J 2005; 26: Suppl. 49, 645s
Year: 2005
Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB)
Source: Annual Congress 2007 - Epidemiology of tuberculosis II
Year: 2007
Sarcoidosis associated with interferon-α therapy for chronic hepatitis C
Source: Eur Respir J 2006; 28: Suppl. 50, 541s
Year: 2006
Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?
Source: Eur Respir J 2007; 29: 347-351
Year: 2007
Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C
Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation
Year: 2019
Risk factors of drug -induced hepatitis among patients with TB/HIV co-infection
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Impact of direct-acting antiviral (DAA) treatment for hepatitis C on pulmonary hemodynamics
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
Antituberculotic drug-induced medicamentous liver damages
Source: Eur Respir J 2004; 24: Suppl. 48, 51s
Year: 2004
Clinical and morphological outcomes of pulmonary tuberculosis concurrent with chronic hepatitis
Source: Eur Respir J 2006; 28: Suppl. 50, 13s
Year: 2006
Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Do different vaccination regimens for BCG and hepatitis B affect the development of allergic disorders in early childhood?
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept